The Phase 3 clinical trial (NCT04294810) investigating atezolizumab in combination with tiragolumab for previously untreated, PD-L1-selected non-small cell lung cancer (NSCLC) reached its primary completion on 2025-12-30. This milestone indicates that the final data for the primary outcome measures have been collected.
Trial design
The study, titled "A Study of Tiragolumab in Combination With Atezolizumab Compared With Placebo in Combination With Atezolizumab in Patients With Previously Untreated Locally Advanced Unresectable or Metastatic PD-L1-Selected Non-Small Cell Lung Cancer," is a Phase 3 trial (NCT04294810). It enrolled 620 participants diagnosed with Non-Small Cell Lung Cancer. The trial's purpose is to evaluate the efficacy and safety of tiragolumab plus atezolizumab compared with placebo plus atezolizumab in participants with previously untreated locally advanced, unresectable or metastatic PD-L1-selected NSCLC, specifically those with no epidermal growth factor receptor (EGFR) mutation or anaplastic lymphoma kinase (ALK) translocation. Participants were randomized in a 1:1 ratio to receive either tiragolumab plus atezolizumab or placebo plus atezolizumab. The primary outcomes for this study were not detailed in the provided data.
What this means
The primary completion of this Phase 3 trial for atezolizumab in combination with tiragolumab marks a significant step in the drug development process. It signifies that all planned data collection for the primary endpoints has concluded. Researchers can now proceed with data analysis, which will eventually lead to the public release of the trial's efficacy and safety results. These future results will be crucial for understanding the potential role of this combination therapy in treating previously untreated, PD-L1-selected non-small cell lung cancer.
Source
The information regarding the primary completion of this trial was obtained from ClinicalTrials.gov, a public database of clinical studies. The update for study NCT04294810, titled "A Study of Tiragolumab in Combination With Atezolizumab Compared With Placebo in Combination With Atezolizumab in Patients With Previously Untreated Locally Advanced Unresectable or Metastatic PD-L1-Selected Non-Small Cell Lung Cancer," was recorded with a primary completion date of 2025-12-30 on clinicaltrials.gov.